BACK Key Statistics, Chart & Performance
The current stock price of BACK is 0.2 USD. In the past month the price decreased by -67.02%. In the past year, price decreased by -93.46%.
BACK Technical Analysis
BACK Financial Highlights
Over the last trailing twelve months BACK reported a non-GAAP Earnings per Share(EPS) of -4.76. The EPS increased by 66.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -993.1% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BACK Forecast & Estimates
7 analysts have analysed BACK and the average price target is 8.41 USD. This implies a price increase of 4107.5% is expected in the next year compared to the current price of 0.2.
For the next year, analysts expect an EPS growth of 69.42% and a revenue growth -100% for BACK
BACK Ownership
BACK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| HCA | HCA HEALTHCARE INC | 16.55 | 117.235B | ||
| THC | TENET HEALTHCARE CORP | 12.17 | 17.224B | ||
| UHS | UNIVERSAL HEALTH SERVICES-B | 9.18 | 13.525B | ||
| ENSG | ENSIGN GROUP INC/THE | 26.77 | 11.419B | ||
| EHC | ENCOMPASS HEALTH CORP | 17.96 | 10.018B | ||
| PACS | PACS GROUP INC | 18.7 | 5.775B | ||
| BKD | BROOKDALE SENIOR LIVING INC | N/A | 3.674B | ||
| CON | CONCENTRA GROUP HOLDINGS PAR | 15.55 | 3.016B | ||
| NHC | NATIONAL HEALTHCARE CORP | N/A | 2.482B | ||
| SEM | SELECT MEDICAL HOLDINGS CORP | 11.85 | 1.916B |
Related stock screener links
View all stocks in the Health Care Facilities Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BACK
Company Profile
IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 2 full-time employees. The company went IPO on 2019-02-13. The firm is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The firm is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The firm is also engaged in providing the precision medicine business. The firm's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.
Company Info
IMAC HOLDINGS INC
3401 Mallory Lane, Suite 100
Franklin TENNESSEE US
Employees: 3
Phone: 18442664622
IMAC HOLDINGS INC / BACK FAQ
Can you describe the business of IMAC HOLDINGS INC?
IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 2 full-time employees. The company went IPO on 2019-02-13. The firm is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The firm is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The firm is also engaged in providing the precision medicine business. The firm's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.
What is the current price of BACK stock?
The current stock price of BACK is 0.2 USD. The price decreased by -52.65% in the last trading session.
Does BACK stock pay dividends?
BACK does not pay a dividend.
How is the ChartMill rating for IMAC HOLDINGS INC?
BACK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is IMAC HOLDINGS INC (BACK) stock traded?
BACK stock is listed on the Nasdaq exchange.
How is the valuation of IMAC HOLDINGS INC (BACK) based on its PE ratio?
IMAC HOLDINGS INC (BACK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.76).
What is the employee count for BACK stock?
IMAC HOLDINGS INC (BACK) currently has 3 employees.